OptiBiotix confirms plan to list skin care subsidiary

OptiBiotix confirms plan to list skin care subsidiary

Life sciences group OptiBiotix Health plc (LON:OPTI) has confirmed its majority owned SkinBioTherapeutics subsidiary is looking to list on AIM. The group has been gearing up for this ever since it announced plans to spin out the skin care business – formerly known as SkinBiotix – last summer.

Shortly after announcing the split, OptiBiotix brought in Martin Hunt as its new chairman, while Catherine O’Neill has since been appointed as chief executive to head up the new business.

See the article in full at ProactiveInvestors.co.uk

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.